Related Experiment Video
Updated: Jan 13, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Integrative Multi-Omics Analysis and Experiments Validation Identify COX5B as a Novel Therapeutic Target for Lung
Lv Ling1, Minying Lu2, Ling Ye3
1Department of Thoracic Surgery, Panyu Hospital of Traditional Chinese Medicine, Guangzhou, 511400, China.
Background:
A significant proportion of patients still cannot benefit from existing targeted therapies and immunotherapies, making the search for new treatment strategies extremely urgent. In this study, we combined integrate public data analysis with experimental validation to identify novel prognostic biomarkers and therapeutic targets for lung adenocarcinoma (LUAD).
Methods:
We analyzed RNA and protein databases to assess the expression levels of cytochrome C oxidase 5B (COX5B) in LUAD. Several computational algorithms were employed to investigate the relationship between COX5B and immune infiltration in LUAD. To further elucidate the role of COX5B in LUAD, we utilized multiple experimental approaches, including quantitative reverse transcription PCR assays, western blot, immunohistochemistry, electron microscopy, flow cytometry, and EdU proliferation assays.
Results:
We revealed that COX5B was significantly elevated in LUAD and positively correlated with poor prognosis of LUAD patients. Analysis of co-expression network indicated that COX5B may take part in the intracellular adenosine triphosphate (ATP) synthesis through the oxidative phosphorylation pathway. There was a negative correlation between COX5B expression and immune infiltration in LUAD. Furthermore, we validated that COX5B levels were significantly elevated in both LUAD tissues and cell lines. Specifically, immunohistochemistry (IHC) assays revealed a 2.32-fold increase of COX5B in tumor tissues compared to that in adjacent normal tissues (p = 0.0044). Additionally, COX5B knockdown disrupted the redox homeostasis, ultimately suppressed the proliferation of LUAD cells. Subsequent investigations demonstrated that berberine effectively targeted COX5B, diminishing its protein expression and consequently inhibiting cell proliferation and tumor growth in LUAD.
Conclusions:
This study established that upregulated COX5B was positive associated with poor patient prognosis in LUAD, elucidating the mechanisms by which berberine targets COX5B to inhibit tumor growth, thereby providing a novel therapeutic target and strategy for the clinical management of LUAD.
Insights
Elevated cytochrome C oxidase 5B (COX5B) in lung adenocarcinoma (LUAD) correlates with poor prognosis. Berberine targets COX5B, inhibiting LUAD cell proliferation and tumor growth, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung adenocarcinoma (LUAD) remains a challenge, with many patients unresponsive to current therapies.
- Novel prognostic biomarkers and therapeutic targets are urgently needed for LUAD treatment.
- This study investigates cytochrome C oxidase 5B (COX5B) as a potential target in LUAD.
Purpose of the Study:
- To identify novel prognostic biomarkers and therapeutic targets for LUAD.
- To investigate the role of COX5B in LUAD progression and its association with immune infiltration.
- To explore berberine as a therapeutic agent targeting COX5B in LUAD.
Main Methods:
- Analysis of public RNA and protein databases for COX5B expression in LUAD.
- Computational analysis of COX5B's relationship with immune infiltration.
- Experimental validation including qPCR, Western blot, IHC, electron microscopy, flow cytometry, and EdU assays.
- Investigation of berberine's effect on COX5B and LUAD cell proliferation.
Main Results:
- COX5B expression is significantly elevated in LUAD tissues and cell lines, correlating with poor prognosis.
- COX5B is linked to adenosine triphosphate (ATP) synthesis via oxidative phosphorylation and negatively correlates with immune infiltration.
- COX5B knockdown suppresses LUAD cell proliferation by disrupting redox homeostasis.
- Berberine effectively reduces COX5B protein levels, inhibiting LUAD cell proliferation and tumor growth.
Conclusions:
- Upregulated COX5B is a prognostic indicator for poor outcomes in LUAD patients.
- Berberine targets COX5B, offering a novel therapeutic strategy for LUAD management.
- COX5B represents a promising therapeutic target for improving LUAD clinical outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...